Castle Biosciences Reports Q3 Revenue Growth and Provides 2026 Revenue Guidance
Castle Biosciences (CSTL) reported a strong third quarter, achieving $102.9 million in revenue, which represents a 24% increase compared to the same period in 2025. CEO Derek Maetzold attributed this performance to disciplined expense management and focused execution across the company's operations. Looking ahead, the company provided a long-term revenue outlook for 2026, projecting figures between $385 million and $395 million. A key driver for this growth is expected to be the TissueCypher test, which management anticipates will see volume growth in the range of 50% to 52%.
Tickers: $CSTL